Categories
Archives
- 2026
- 2025
- 2024
- 2023
Mar
19
Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star
Mar
09
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Mar
06
Putting People First to Create a More Sustainable Healthcare System
Feb
28
UCB on Growth Path for a Decade Plus
Feb
22
Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases
Jan
03
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
Dec
02
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
Dec
01
Media Statement on levetiracetam (KEPPRA® and KEPPRA XR®) and DRESS
Nov
17
Employee Spotlight: Stephen Mayclin’s Impact as a Working for Cures Champion and R&D Advocate